Details

Details

Title Case Comprehensive Cancer Center Affiliated Translational Research in CLL and Hematological Malignancies

IRB CASE2911

CC 13-1097

Hospital Main Campus

Disease Hematologic Malignancy, Leukemia - Chronic Lymphocytic (CLL), Lymphoma

Description

Description

Primary objectives
  1. Institute a standard peripheral blood sample collection from patients with Chronic Lymphocytic Leukemia (CLL) and other hematologic malignancies for in vitro studies across institutions of the Case Comprehensive Cancer Center.
  2. Institute a standard bone marrow sample collection from patients with CLL and other hematologic malignancies for in vitro studies across institutions of the Case Comprehensive Cancer Center.
  3. Establish a formal mechanism of sharing samples among basic science laboratories.
  4. Perform a long term follow up study of a large cohort of CLL patients to identify the importance of old and new risk factors as well as identify other parameters that may affect the course of the disease as well as to validate old or new prognostic parameters.
Secondary objectives
  1. Establish a collaborative translational effort in the research of CLL between the participating members of the Case Comprehensive Cancer Center.
  2. Establish a collaborative research network for hematologic malignancy research among members of the Case Comprehensive Cancer Center
Inclusion Criteria

Inclusion Criteria

  1. Age ≥ 18 years
  2. Diagnosis of untreated or previously treated Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma (SLL), Monoclonal B cell Lymphocytosis and B cell prolymphocytic leukemia
  3. CLL, defined as the presence of at least 5 x 109 B lymphocytes/L (5000/μL) in the peripheral blood, with confirmation of the clonality and immunophenotype of the circulating B lymphocytes by flow cytometry.
  4. SLL: Small Lymphocytic Lymphoma (SLL) with presence of lymphadenopathy and/or splenomegaly and confirmed by biopsy, with circulating B lymphocytes in the peripheral blood not exceeding 5 x 109/L.
  5. Monoclonal B lymphocytosis (MBL): absolute increase in clonal B lymphocytes, not exceeding 5 x 109/L and in absence of lymphadenopathy, organomegaly, cytopenias or disease - related symptoms.
  6. B cell prolymphocytic leukemia (B-PLL), is diagnosed with an increase in ciruculating lymphocytes exceeding 5 x 109/L and with more than 55% of these being prolymphoctes.

    OR

  7. Diagnosis of Non - CLL hematologic malignancy, including Acute Myeloid Leukemia, Myelodysplastic Syndrome, Myeloproliferative Syndrome, Chronic Myeloid Leukemia, Acute Lymphoblastic Leukemia, Multiple Myeloma, Non Hodgkin Lymphoma. Patients with any of these diagnoses will be enrolled to provide comparable samples for correlative studies but NOT for participation in the database study.
Exclusion Criteria

Exclusion Criteria

  1. Inability to provide consent.

    NOTE: Participation in other research protocols, including therapeutic, observational as well as biorepository or database studies, does not constitute an exclusion criterion.